For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Etoricoxib - Pain & inflammation - musculoskeletal
PAD Profile : Etoricoxib - Pain & inflammation - musculoskeletal Important
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Celecoxib
- Diclofenac sodium
- Diclofenac sodium
- Naproxen
- Ibuprofen
- Naproxen
- Meloxicam
- Aceclofenac
- Diclofenac potassium
- Indometacin
- Nabumetone
- Etodolac
- Ketoprofen
- Mefenamic acid
Other Indications
Additional Documents
Committee Recommendations
The Surrey & North West Sussex Area Prescribing Committee recommends etoricoxib as a treatment option for the treatment of pain and inflammation in line with the product licence*.
Etoricoxib will be considered as GREEN on the traffic light system as a 2nd line COX-2 inhibitor (after celecoxib) for use where a COX-2 inhibitor is indicated.
If etoricoxib is indicated for the treatment of gouty arthritis then etoricoxib should be considered before celecoxib as it is licensed for this indication.
*Licenced for: Osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute gouty arthritis
The branded product, Arcoxia, is considered BLACK. Please prescribe generically for this indication.